Please assess the completion status of the following clinical trial:

Trial Title: Open Label, 4 Week Study of ITCA 650 in Adults With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* type 2 diabetes \>6 months~* stable diet \& exercise, metformin, TZD or met + TZD HbA1c \>6.5% \<10.0%~Exclusion Criteria:~* prior treatment with exenatide~* history of pancreatitis~* history of medullary thyroid cancer or multiple endocrine neoplasia 2

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 10 mcg./day (Type: EXPERIMENTAL): ITCA 650 (exenatide in DUROS)
- 20 mcg/day (Type: EXPERIMENTAL): ITCA 650 (exenatide in DUROS)
- 40 mcg/day (Type: EXPERIMENTAL): ITCA 650 (exenatide in DUROS)
- 80 mcg/day (Type: EXPERIMENTAL): ITCA 650 (exenatide in DUROS)

Based on this trial design, predict the completion outcome and termination type (if applicable).